PT856520E - Metodo de preparacao de um anticorpo monoclonal, anticorpo monoclonal, uma composicao farmaceutica e um reagente de diagnostico - Google Patents
Metodo de preparacao de um anticorpo monoclonal, anticorpo monoclonal, uma composicao farmaceutica e um reagente de diagnosticoInfo
- Publication number
- PT856520E PT856520E PT97203769T PT97203769T PT856520E PT 856520 E PT856520 E PT 856520E PT 97203769 T PT97203769 T PT 97203769T PT 97203769 T PT97203769 T PT 97203769T PT 856520 E PT856520 E PT 856520E
- Authority
- PT
- Portugal
- Prior art keywords
- monoclonal antibody
- antigens
- cells
- preparing
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96203465 | 1996-12-06 | ||
| EP97201972 | 1997-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT856520E true PT856520E (pt) | 2006-08-31 |
Family
ID=26143410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97203769T PT856520E (pt) | 1996-12-06 | 1997-12-02 | Metodo de preparacao de um anticorpo monoclonal, anticorpo monoclonal, uma composicao farmaceutica e um reagente de diagnostico |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US6020170A (pt) |
| EP (1) | EP0856520B1 (pt) |
| JP (1) | JPH10179160A (pt) |
| KR (1) | KR100543053B1 (pt) |
| AT (1) | ATE322507T1 (pt) |
| AU (1) | AU733165B2 (pt) |
| BR (1) | BR9706236A (pt) |
| CA (1) | CA2221682C (pt) |
| DE (1) | DE69735621T2 (pt) |
| DK (1) | DK0856520T3 (pt) |
| ES (1) | ES2262170T3 (pt) |
| HU (1) | HUP9702359A3 (pt) |
| IL (1) | IL122233A (pt) |
| NO (1) | NO327047B1 (pt) |
| NZ (1) | NZ329314A (pt) |
| PL (1) | PL193821B1 (pt) |
| PT (1) | PT856520E (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69934250T2 (de) * | 1998-12-22 | 2007-05-24 | Raven Biotechnologies, Inc., South San Francisco | Zusammensetzungen und verfahren zur herstellung monoklonaler antikörper, repräsentativ für einen spezifischen zelltyp |
| SE9902817D0 (sv) | 1999-07-30 | 1999-07-30 | A & Science Invest Ab | A method for selective electrofusion of at least two fusion partners having cell-like membranes |
| CZ20021356A3 (cs) * | 1999-10-18 | 2002-07-17 | Akzo Nobel N. V. | Modifikovaný peptid a farmaceutický prostředek |
| US6541225B1 (en) | 2000-01-26 | 2003-04-01 | Raven Biotechnologies, Inc. | Methods and compositions for generating human monoclonal antibodies |
| DE60129572T2 (de) | 2000-08-14 | 2008-04-17 | N.V. Organon | Verwendung von antikörpern gegen spezifische mhc-peptidkomplexe |
| BR0211468A (pt) * | 2001-07-24 | 2004-11-23 | Univ Yale | Métodos de tratar e de prevenir uma doença inflamátoria em um mamìfero e de identificar um composto útil para tratar uma doença inflamatória em um mamìfero, composto, e kits para tratar e para prevenir uma doença inflamatória em um mamìfero |
| US7018819B2 (en) * | 2001-11-30 | 2006-03-28 | Cellectricon Ab | Method and apparatus for manipulation of cells and cell-like structures focused electric fields in microfludic systems and use thereof |
| KR20060002879A (ko) * | 2003-03-28 | 2006-01-09 | 자이단호진 토야마켄 신세키 산교기코 | 1개의 항원 특이적 b림프구를 이용한 항원 특이적 항체를생산하는 하이브리도마의 제조방법 및 단일 클론 항체의제조방법 |
| US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
| EP1660186B1 (en) | 2003-08-18 | 2013-12-25 | MedImmune, LLC | Humanization of antibodies |
| EP1729805A4 (en) * | 2004-02-25 | 2008-11-26 | Medimmune Inc | METHODS AND COMPOSITIONS RELATED TO CHITINASES AND CHITINASE-MOLECULARS AND MODULATION OF OSTEOCLASTS |
| AU2005325801A1 (en) * | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| JP5153613B2 (ja) | 2005-03-18 | 2013-02-27 | メディミューン,エルエルシー | 抗体のフレームワーク・シャッフル |
| EP1893647A2 (en) | 2005-06-23 | 2008-03-05 | MedImmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
| EP1928496A4 (en) * | 2005-08-31 | 2011-01-05 | Medimmune Inc | C / CLP ANTAGONISTS AND METHOD OF USE |
| DE112009000064T5 (de) * | 2008-01-09 | 2010-11-04 | LenSx Lasers, Inc., Aliso Viejo | Photodisruptive Laserfragmentierung von Gewebe |
| US20160075766A1 (en) * | 2013-05-21 | 2016-03-17 | Roche Diagnostics Operations, Inc. | Method for producing antibodies using ovine b-cells and uses thereof |
| JP7166342B2 (ja) | 2017-11-30 | 2022-11-07 | エフ.ホフマン-ラ ロシュ アーゲー | B細胞培養法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4550086A (en) * | 1983-02-16 | 1985-10-29 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that recognize human T cells |
| EP0255547A1 (en) * | 1986-07-29 | 1988-02-10 | Kishimoto, Tadamitsu, Prof. | Monoclonal antibodies specific to surface receptor for IgE and hybrid cell lines producing these antibodies and use thereof |
| US5766947A (en) * | 1988-12-14 | 1998-06-16 | Astra Ab | Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor |
| US5223426A (en) * | 1988-12-15 | 1993-06-29 | T Cell Sciences, Inc. | Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor |
| US5162223A (en) * | 1989-02-17 | 1992-11-10 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Resources | Hybridomas and resulting monoclonal antibodies directed against antigens of Bordetella pertussis |
| US5473051A (en) * | 1990-07-19 | 1995-12-05 | The Scripps Research Institute | Inhibition of Mac-1 receptor binding to fibrinogen using D30 homologs |
| ES2103770T3 (es) * | 1990-11-26 | 1997-10-01 | Akzo Nobel Nv | Procedimiento de produccion de anticuerpos monoclonales. |
| CA2250166A1 (en) * | 1996-03-28 | 1997-10-02 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
-
1997
- 1997-11-18 IL IL12223397A patent/IL122233A/en not_active IP Right Cessation
- 1997-11-25 CA CA2221682A patent/CA2221682C/en not_active Expired - Fee Related
- 1997-11-27 JP JP9363807A patent/JPH10179160A/ja active Pending
- 1997-12-02 ES ES97203769T patent/ES2262170T3/es not_active Expired - Lifetime
- 1997-12-02 DE DE69735621T patent/DE69735621T2/de not_active Expired - Lifetime
- 1997-12-02 DK DK97203769T patent/DK0856520T3/da active
- 1997-12-02 EP EP97203769A patent/EP0856520B1/en not_active Expired - Lifetime
- 1997-12-02 AT AT97203769T patent/ATE322507T1/de not_active IP Right Cessation
- 1997-12-02 PT PT97203769T patent/PT856520E/pt unknown
- 1997-12-03 NZ NZ329314A patent/NZ329314A/xx unknown
- 1997-12-04 BR BR9706236A patent/BR9706236A/pt active Search and Examination
- 1997-12-05 AU AU46908/97A patent/AU733165B2/en not_active Ceased
- 1997-12-05 HU HU9702359A patent/HUP9702359A3/hu unknown
- 1997-12-05 NO NO19975714A patent/NO327047B1/no not_active IP Right Cessation
- 1997-12-05 KR KR1019970066848A patent/KR100543053B1/ko not_active Expired - Fee Related
- 1997-12-05 PL PL323572A patent/PL193821B1/pl not_active IP Right Cessation
- 1997-12-05 US US08/985,898 patent/US6020170A/en not_active Expired - Lifetime
-
1999
- 1999-09-27 US US09/405,745 patent/US6392020B1/en not_active Expired - Lifetime
-
2001
- 2001-11-01 US US09/985,065 patent/US20020143150A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK0856520T3 (da) | 2006-07-31 |
| US6020170A (en) | 2000-02-01 |
| HUP9702359A2 (hu) | 1998-09-28 |
| ATE322507T1 (de) | 2006-04-15 |
| PL323572A1 (en) | 1998-06-08 |
| MX9709446A (es) | 1998-07-31 |
| HU9702359D0 (en) | 1998-03-02 |
| EP0856520A1 (en) | 1998-08-05 |
| US20020143150A1 (en) | 2002-10-03 |
| NO975714D0 (no) | 1997-12-05 |
| ES2262170T3 (es) | 2006-11-16 |
| NO327047B1 (no) | 2009-04-14 |
| NO975714L (no) | 1998-06-08 |
| IL122233A (en) | 2001-04-30 |
| CA2221682C (en) | 2011-10-18 |
| PL193821B1 (pl) | 2007-03-30 |
| DE69735621T2 (de) | 2006-08-24 |
| NZ329314A (en) | 1999-02-25 |
| BR9706236A (pt) | 1999-05-04 |
| EP0856520B1 (en) | 2006-04-05 |
| AU733165B2 (en) | 2001-05-10 |
| HUP9702359A3 (en) | 2001-11-28 |
| AU4690897A (en) | 1998-06-11 |
| DE69735621D1 (de) | 2006-05-18 |
| IL122233A0 (en) | 1998-04-05 |
| JPH10179160A (ja) | 1998-07-07 |
| US6392020B1 (en) | 2002-05-21 |
| KR19980063909A (ko) | 1998-10-07 |
| KR100543053B1 (ko) | 2006-06-13 |
| CA2221682A1 (en) | 1998-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT856520E (pt) | Metodo de preparacao de um anticorpo monoclonal, anticorpo monoclonal, uma composicao farmaceutica e um reagente de diagnostico | |
| DE69133179D1 (de) | Katalytische antikörperkomponente | |
| ATE200679T1 (de) | Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen | |
| PT699755E (pt) | Metodo para obtencao de imunoglobulinas modificadas com imunogenicidade reduzida de dominios variaveis de anticorpos de murideo composicoes que as contem | |
| AU648591B2 (en) | Hydrophilic polypeptide spacer | |
| DE69632667D1 (de) | CTLA4-Mutantmoleküle und deren Verwendung | |
| DE69724428D1 (de) | Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren | |
| ATE196607T1 (de) | Verfahren zur ex vivo-immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer antikörper | |
| PT733069E (pt) | Antigenios ctla-8 de primata purificados e reagentes relacionados | |
| BR9809656A (pt) | Composição imunopotencializante | |
| DE3750342D1 (de) | Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen. | |
| EP0350690A3 (de) | Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente | |
| DE69834808D1 (de) | Multiple,kohlenhydrathaltige glycopeptid-antigene, daraus entwickelte impfstoffe sowie deren verwendung | |
| ATE317269T1 (de) | Methoden und zusammensetzungen zur erhöhung der immunantwort und zur herstellung von in-vitro monoklonalen antikörpern (mabs) | |
| ES2056919T3 (es) | Anticuerpo monoclonal especifico para la fosfolipasa a2 pancreatica humana. | |
| OA08334A (fr) | Protéines de différentiation acino-foetales associées au cancer du pancréas, antisérum et anticorps monoclonaux contre ces protéines, procédés de préparation. | |
| DE69020914D1 (de) | Monoklonale Antikörper von Ratten gegen menschliche Antigene und Verfahren zu deren Herstellung. | |
| NO874405L (no) | Fremgangsmaate til bestemmelse av naervaer av diagnostisk relevante stoffer, spesielt antistoffer eller antigener etter elisa-metoden ved fotometrisk vurdering. | |
| IT8821547A0 (it) | Metodo immunologico per la determinazione di anticorpi anti antigeni di microorganismi, mediante anticorpi antiidiotipo e mezzi adatti allo scopo. | |
| ATE239754T1 (de) | An nukleinsäure gebundenes polypeptid, verfahren zur herstellung eines an nukleinsäure gebundenen polypeptides und immunoassay, in dem dieses polypeptid verwendung findet |